National Eye Institute (NEI)
593
82
111
387
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.1%
48 terminated/withdrawn out of 593 trials
89.0%
+2.5% vs industry average
21%
126 trials in Phase 3/4
40%
155 of 387 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (593)
Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
Role: collaborator
Clinical and Molecular Studies in Families With Inherited Eye Disease
Role: lead
Screening for Research Participants
Role: lead
Age-Related Eye Disease Study (AREDS) Follow-Up
Role: lead
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
Role: lead
Simulated Walking With Multiplexing Prism for Field Expansion in Monocular Vision
Role: collaborator
Peripheral Retina Robotically Aligned OCT Study
Role: collaborator
RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)
Role: collaborator
Rod and Cone Mediated Function in Retinal Disease
Role: lead
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions
Role: lead
Study on Moebius Syndrome and Congenital Facial Weakness Disorders
Role: collaborator
Natural History of Eye Diseases Related to ABCA4 Mutations
Role: lead
Study of Dark Adaptation in Age-Related Macular Degeneration
Role: lead
Optic Nerve Head Strain in Non-glaucoma Subjects
Role: collaborator
Cell Collection to Study Eye Diseases
Role: lead
Dark Adaptation in Participants With Age-Related Macular Degeneration
Role: lead
Perception, Sensation, Cognition and Action in Humans
Role: lead
AMD Ryan Initiative Study (ARIS)
Role: lead
Uveitis/Intraocular Inflammatory Disease Biobank (iBank)
Role: lead
Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes
Role: collaborator